Frontiers in Immunology (Sep 2022)
PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study
- Ke Su,
- Lu Guo,
- Wenqiong Ma,
- Jing Wang,
- Yunchuan Xie,
- Mingyue Rao,
- Jianwen Zhang,
- Xueting Li,
- Lianbin Wen,
- Bo Li,
- Bo Li,
- Bo Li,
- Xiaoli Yang,
- Xiaoli Yang,
- Xiaoli Yang,
- Yanqiong Song,
- Weihong Huang,
- Hao Chi,
- Tao Gu,
- Ke Xu,
- Yanlin Liu,
- Jiali Chen,
- Zhenying Wu,
- Yi Jiang,
- Han Li,
- Hao Zeng,
- Pan Wang,
- Xunjie Feng,
- Siyu Chen,
- Binbin Yang,
- Hongping Jin,
- Kun He,
- Yunwei Han,
- Yunwei Han,
- Yunwei Han
Affiliations
- Ke Su
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Lu Guo
- Department of Ophthalmology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Wenqiong Ma
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Jing Wang
- Clinical Research Institute, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Yunchuan Xie
- Department of Radiology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Mingyue Rao
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Jianwen Zhang
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Xueting Li
- Department of Oncology, 363 Hospital, Chengdu, China
- Lianbin Wen
- Department of Geriatric Cardiology, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, China
- Bo Li
- Department of General Surgery (Hepatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Bo Li
- Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, China
- Bo Li
- Academician (Expert) Workstation of Sichuan Province, Luzhou, China
- Xiaoli Yang
- Department of General Surgery (Hepatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Xiaoli Yang
- Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, China
- Xiaoli Yang
- Academician (Expert) Workstation of Sichuan Province, Luzhou, China
- Yanqiong Song
- 0Department of Radiotherapy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
- Weihong Huang
- 1Clinical Medical College, Southwest Medical University, Luzhou, China
- Hao Chi
- 1Clinical Medical College, Southwest Medical University, Luzhou, China
- Tao Gu
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Ke Xu
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Yanlin Liu
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Jiali Chen
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Zhenying Wu
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Yi Jiang
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Han Li
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Hao Zeng
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Pan Wang
- 2Clinical Skills Center, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Xunjie Feng
- 1Clinical Medical College, Southwest Medical University, Luzhou, China
- Siyu Chen
- 1Clinical Medical College, Southwest Medical University, Luzhou, China
- Binbin Yang
- 1Clinical Medical College, Southwest Medical University, Luzhou, China
- Hongping Jin
- 1Clinical Medical College, Southwest Medical University, Luzhou, China
- Kun He
- Clinical Research Institute, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Yunwei Han
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Yunwei Han
- Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, China
- Yunwei Han
- Academician (Expert) Workstation of Sichuan Province, Luzhou, China
- DOI
- https://doi.org/10.3389/fimmu.2022.972503
- Journal volume & issue
-
Vol. 13
Abstract
BackgroundWhether intensity-modulated radiotherapy (IMRT) can enhance the efficacy of the programmed death (PD)-1 inhibitors combined with anti-angiogenic therapy for hepatocellular carcinoma (HCC) is unclear. Therefore, we conducted this multicenter retrospective study to investigate the efficacy of the combination of PD-1 inhibitors with anti-angiogenic therapy and IMRT.MethodsFrom April 2019 to March 2022, a total of 197 patients with HCC [combination of PD-1 inhibitors with anti-angiogenic therapy and IMRT (triple therapy group), 54; PD-1 inhibitors plus anti-angiogenic therapy (control group), 143] were included in our study. Propensity score matching (PSM) was applied to identify two groups with similar baselines. The objective response rate (ORR), overall survival (OS), and progression-free survival (PFS) of the two groups were compared before and after matching.ResultsPrior to PSM, the triple therapy group had higher ORR (42.6% vs 24.5%, P = 0.013) and more superior median OS (mOS) (20.1 vs 13.3 months, P = 0.009) and median PFS (mPFS) (8.7 vs 5.4 months, P = 0.001) than the control group. Following PSM, the triple therapy group still exhibited better mPFS (8.7 vs 5.4 months, P = 0.013) and mOS (18.5 vs 12.6 months, P = 0.043) than the control group. However, the ORR of the two groups was similar (40% vs 25%, P = 0.152). No significant difference was observed in the treatment-related adverse events between the two groups (P < 0.05 for all). ConclusionsThe combination of PD-1 inhibitors with anti-angiogenic therapy and IMRT for HCC is a promising regimen.
Keywords
- programmed death-1 inhibitors
- anti-angiogenic therapy
- intensity-modulated radiotherapy
- hepatocellular carcinoma
- propensity score matching
